Brief Title
Different Phenotypes of Bronchiectasis
Official Title
Different Phenotypes of Bronchiectasis
Brief Summary
Bronchiectasis is defined as abnormal chronic dilatation of one or more bronchi. Patients have a structural abnormality of the bronchial wall that predisposes them to bacterial infection likely due to impaired mucus clearance. A vicious cycle of chest infections and chronic lung inflammation can lead to further damage of the bronchial wall and spread of disease to normal areas of bystander lung.
Detailed Description
A search for an underlying cause, which may be amenable to a targeted intervention to prevent ongoing damage, is essential but often fruitless, and the focus of therapy rapidly turns to empiric treatments to prevent infective exacerbations and retard disease progression. The British Thoracic Society Bronchiectasis management guidelines provide an in-depth summary of the available literature and are an excellent tool for guiding treatment decision making. However, they do not provide guidance on which patients are most likely to benefit from specific interventions.Disease severity in bronchiectasis is hard to define. Radiological severity grading scores exist; however, there is often a disconnect between radiological severity, symptom burden and disease progressionIn 2014, competing bronchiectasis severity scores were published (FACED and the Bronchiectasis Severity Index (BSI). In each of these, a combination of patient demographics, symptom scores, comorbidities, and clinical, radiological and microbiological parameters were used to construct scoring systems. In case of the BSI, it predicted future mortality, and in the case of FACED, extended to prediction of future exacerbation frequency, hospitalisation and quality of life.These severity scores have utility in identifying an individual's risk of disease progression to a predefined outcome and aid in sub classifying this heterogeneous group of patients in a manner that may pave the way to future mechanistic studies, which explain how these different disease phenotypes arise and inform the development of targeted therapeutics.
Study Type
Observational
Primary Outcome
( Severity of Bronchiectasis will be measured according to BSI scoring system and FACED scoring system
Secondary Outcome
management of bronchectasis according to severity index
Condition
Bronchiectasis
Intervention
Pulmonary function tests,Bronchiectasis severity index score
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Combination Product
Estimated Enrollment
100
Start Date
July 1, 2017
Completion Date
January 1, 2019
Primary Completion Date
September 1, 2018
Eligibility Criteria
Inclusion Criteria: patient diagnosed as bronchiectasis according to clinical picture and high- resolution computed tomography scan of the chest. can perform pulmonary function test. Exclusion Criteria: No
Gender
All
Ages
18 Years - 70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
Maha El-kholy, Prof, ,
Location Countries
Egypt
Location Countries
Egypt
Administrative Informations
NCT ID
NCT03262064
Organization ID
DPOB
Responsible Party
Principal Investigator
Study Sponsor
Assiut University
Study Sponsor
Maha El-kholy, Prof, Study Director,
Verification Date
September 2017